SLF
AKBA icon

Sun Life Financial’s Akebia Therapeutics AKBA Stock Holding History

Sun Life Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-34,356
Closed -$135K – 468
2019
Q3 		$135K Buy
34,356
+194
+0.6% +$831 0.03% 216
2019
Q2 		$165K Buy
34,162
+2,907
+9% +$16.5K 0.04% 198
2019
Q1 		$256K Buy
+31,255
New +$214K 0.06% 168
2018
Q3 		– Sell
-19,315
Closed -$193K – 623
2018
Q2 		$193K Buy
+19,315
New +$193K 0.03% 231

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sun Life Financial's AKBA Position: Q4 2019 in Review

Sun Life Financial sold out of Akebia Therapeutics (AKBA) in Q4 2019, closing a stake of 34,356 shares — an estimated $135K sold.

Sun Life Financial first reported a position in AKBA in Q2 2018 and held it in 4 quarters. The position peaked at $256K in Q1 2019. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

  • Sun Life Financial reported no remaining Akebia Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sun Life Financial sold 34,356 Akebia Therapeutics shares in Q4 2019, an estimated $135K.
  • Sun Life Financial first reported a position in Akebia Therapeutics in Q2 2018 and held it in 4 quarters.
  • Sun Life Financial's Akebia Therapeutics position peaked at $256K in Q1 2019.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Sun Life Financial's 13F filing for Q4 2019, filed 10 Feb 2020.